Edition:
United Kingdom

Aptevo Therapeutics Inc (APVO.OQ)

APVO.OQ on NASDAQ Stock Exchange Global Select Market

4.27USD
3:38pm BST
Change (% chg)

$0.05 (+1.18%)
Prev Close
$4.22
Open
$4.22
Day's High
$4.27
Day's Low
$4.18
Volume
2,758
Avg. Vol
35,476
52-wk High
$4.85
52-wk Low
$1.18

Select another date:

Mon, Jan 8 2018

BRIEF-Aptevo Therapeutics Begins Patient Dosing In Phase 2 Clinical Trial Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS BEGINS PATIENT DOSING IN PHASE 2 CLINICAL TRIAL OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA Source text for Eikon: Further company coverage:

BRIEF-Aptevo Therapeutics Announces Plans To Conduct Phase 2 Study Of Otlertuzumab In Peripheral T-Cell Lymphoma

* APTEVO THERAPEUTICS ANNOUNCES PLANS TO CONDUCT PHASE 2 STUDY OF OTLERTUZUMAB IN PERIPHERAL T-CELL LYMPHOMA

BRIEF-Aptevo Therapeutics files mixed shelf of up to $150 mln

* Aptevo Therapeutics Inc files for mixed shelf of up to $150 million - SEC filing‍​ Source text for Eikon: (http://bit.ly/2hvzJMI) Further company coverage:

BRIEF-Aptevo Therapeutics reports third quarter 2017 financial results

* Aptevo Therapeutics reports third quarter 2017 financial results

Select another date: